Search Results 951-960 of 17009 for monoclonal antibody

1. A Study to Evaluate the Safety and Effectiveness of TEPEZZA® in Treating Patients with Chronic (Inactive) Thyroid Eye Disease - Mayo Clinic

   Treatment with any monoclonal antibody within 3 months prior to Screening. Identified pre-existing ophthalmic disease that, in the judgment of the ...

2. Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy - Mayo Clinic

   We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the ...

3. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

   Part 2 (Cohort Expansion): Subjects must have received adequate prior therapy including at a minimum including at a minimum anti-CD20 monoclonal antibody ...

4. Benralizumab for Eosinophilic Esophagitis - Mayo Clinic

   Receipt of any marketed or investigational biologic (monoclonal or polyclonal antibody) within 4 months or 5 half-lives prior to the date informed consent ...

5. Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

   formulations or history of severe infusion-related reactions to monoclonal antibodies - Any other active malignancy at time of randomization or diagnosis of ...

6. A Phase 2, Multicenter, Randomized Study of AP26113 - Mayo Clinic

   Received monoclonal antibodies or had major surgery within 30 days of the first dose of AP26113 (Day 1, Cycle 1). Have been diagnosed with another primary ...

7. Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma - Mayo Clinic

   Subjects must have received adequate prior therapy including at a minimum: Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 ...

8. J&J Vaccine Booster in Transplant Recipients - Mayo Clinic

   S vaccine (JNJ-78436735, aka the J&J vaccine, a viral vector vaccine) increases anti-COVID spike protein antibody ... investigational monoclonal antibodies within ...

9. Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) - Mayo Clinic

   ... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. * Has had a prior anti-cancer monoclonal antibody (mAb), excluding anti ...

10. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors - Mayo Clinic

    ... monoclonal antibodies): 2 weeks. Immune-checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4), monoclonal antibodies, antibody-drug conjugates ...